Pfizer obesity pill delivers 15% average weight loss in phase 3 trial

Pfizer says its experimental obesity pill produced an average 15% reduction in body weight over 52 weeks in a phase 3 trial, a result that could strengthen the company’s push into the fast-growing weight-loss market.

According to the Reuters report, the oral treatment outperformed placebo in the pivotal study of adults with obesity. The findings suggest the drug may offer a convenient alternative to injectable therapies that currently dominate the sector.

Late-stage trial data are an important step, but the drug still faces regulatory review before it can reach patients. Safety, durability of weight loss, and real-world tolerability will likely remain key questions for doctors, investors, and regulators.

Pfizer has been working to build a stronger presence in obesity treatment as demand for effective therapies continues to rise worldwide. If approved, the pill could broaden access by giving patients a once-daily oral option in a market now led by injections.